Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: Using Monte Carlo simulations to predict doses for specified pharmacodynamic targets

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5868-5873

  Patel, Kashyap ^a   Roberts, Jason A ^a,b   Lipman, Jeffrey ^a,b   Tett, Susan E ^a   Deldot, Megan E ^a   Kirkpatrick, Carl M ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANURIA; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CLINICAL ARTICLE; CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY TUBULE ABSORPTION; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PREDICTION; PRIORITY JOURNAL; STEADY STATE; TREATMENT OUTCOME;

AGED; ANTIFUNGAL AGENTS; ANURIA; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUCONAZOLE; HEMODIAFILTRATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PREDICTIVE VALUE OF TESTS;

EID: 81555208494     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00424-11     Document Type: Article

References (39)

1. Andes, D. 2003. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 47:1179-1186. (Pubitemid 36368572)
2. Arredondo, G., R. Martinez-Jorda, R. Calvo, C. Aguirre, and E. Suarez. 1994. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int. J. Clin. Pharmacol. Ther. 32:361-364. (Pubitemid 24212082)
3. Bellomo, R., et al. 2009. Intensity of continuous renal-replacement therapy in critically ill patients. N. Engl. J. Med. 361:1627-1638.
4. Bergner, R., et al. 2006. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg. Nephrol. Dial. Transplant. 21:1019-1023.
5. Boeckmann, A. J., L. B. Sheiner, and S. Beal. 1994. NONMEM users guide-part V: introductory guide. NONMEM Project Group, University of California at San Francisco, San Francisco, CA.
6. Choi, G., et al. 2009. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 37:2268-2282.
7. Clancy, C. J., V. L. Yu, A. J. Morris, D. R. Snydman, and M. H. Nguyen. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177. (Pubitemid 41060556)
8. Cousin, L., M. L. Berre, V. Launay-Vacher, H. Izzedine, and G. Deray. 2003. Dosing guidelines for fluconazole in patients with renal failure. Nephrol. Dial. Transplant. 18:2227-2231. (Pubitemid 37336807)
9. Debruyne, D. 1997. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin. Pharmacokinet. 33:52-77. (Pubitemid 27307002)
10. Debruyne, D., and J. P. Ryckelynck. 1993. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:10-27. (Pubitemid 23042127)
11. Dufour, G., and P. Montravers. 2009. Pharmacokinetics of antibiotics or antifungal drugs in intensive care units. Curr. Infect. Dis. Rep. 11:14-20.
12. Heintz, B. H., G. R. Matzke, and W. E. Dager. 2009. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29:562-577.
13. Joy, M. S., G. R. Matzke, D. K. Armstrong, M. A. Marx, and B. J. Zarowitz. 1998. A primer on continuous renal replacement therapy for critically ill patients. Ann. Pharmacother. 32:362-375. (Pubitemid 28120354)
14. Kishino, S., et al. 2001. Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. Ther. Drug Monit. 23:4-8. (Pubitemid 32105958)
15. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474. (Pubitemid 29083057)
16. Kumar, A., et al. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34:1589-1596. (Pubitemid 43810035)
17. Lam, Y. W., S. Banerji, C. Hatfield, and R. L. Talbert. 1997. Principles of drug administration in renal insufficiency. Clin. Pharmacokinet. 32:30-57. (Pubitemid 27037847)
18. Levy, E. M., C. M. Viscoli, and R. I. Horwitz. 1996. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275:1489-1494. (Pubitemid 26140761)
19. McLachlan, A. J., A. S. Gross, J. L. Beal, I. Minns, and S. E. Tett. 2001. Analytical validation for a series of marker compounds used to assess renal drug elimination processes. Ther. Drug Monit. 23:39-46. (Pubitemid 32105963)
20. Muhl, E., T. Martens, H. Iven, P. Rob, and H. P. Bruch. 2000. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur. J. Clin. Pharmacol. 56:671-678. (Pubitemid 32204487)
21. Pai, M. P., R. S. Turpin, and K. W. Garey. 2007. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 51:35-39. (Pubitemid 46047684)
22. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
23. Pappas, P. G., et al. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189. (Pubitemid 38113025)
24. Parke, J., N. H. Holford, and B. G. Charles. 1999. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Computer Methods Programs Biomed. 59:19-29. (Pubitemid 29125558)
25. Patel, K., and C. M. J. Kirkpatrick. Pharmacokinetic concepts revisited-basic and applied. Curr. Pharm. Biotechnol., in press.
26. Pittrow, L., and A. Penk. 1999. Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycoses 42:17-19. (Pubitemid 29256320)
27. Playford, E. G., J. Lipman, and T. C. Sorrell. 2010. Management of invasive candidiasis in the intensive care unit. Drugs 70:823-839.
28. Reetze-Bonorden, P., J. Bohler, and E. Keller. 1993. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clinical Pharmacokinet. 24:362-379. (Pubitemid 23135684)
29. Roberts, J. A., C. M. J. Kirkpatrick, and J. Lipman. 2010. Monte-Carlo simulations: maximizing antibiotic pharmacokinetic data to optimise clinical practice for critically ill patients. J. Antimicrob. Chemother. 66:227-231.
30. Roberts, J. A., and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:840-851.
31. Roos, J. F., C. M. J. Kirkpatrick, S. E. Tett, A. J. McLachlan, and S. B. Duffull. 2008. Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. Br. J. Clin. Pharmacol. 66:455-466.
32. Schetz, M., P. Ferdinande, G. Van den Berghe, C. Verwaest, and P. Lauwers. 1995. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med. 21:612-620.
33. Schetz, M., P. Lauwers, and P. Ferdinande. 1989. Extracorporeal treatment of acute renal failure in the intensive care unit: a critical view. Intensive Care Med. 15:349-357. (Pubitemid 19236050)
34. Tam, V. H., S. Kabbara, R. F. Yeh, and R. H. Leary. 2006. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob. Agents Chemother. 50:3950-3952. (Pubitemid 44684925)
35. Tett, S. E., C. M. J. Kirkpatrick, A. S. Gross, and A. J. McLachlan. 2003. Principles and clinical application of assessing alterations in renal elimination pathways. Clin. Pharmacokinet. 42:1193-1211. (Pubitemid 37491486)
36. Trotman, R. L., J. C. Williamson, D. M. Shoemaker, and W. L. Salzer. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41:1159-1166. (Pubitemid 41429480)
37. Uchino, S., et al. 2005. Acute renal failure in critically ill patients: a multi-national, multicenter study JAMA 294:813-818. (Pubitemid 41175724)
38. Valtonen, M., E. Tiula, and P. J. Neuvonen. 1997. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J. Antimicrob. Chemother. 40:695-700. (Pubitemid 27504001)
39. Yagasaki, K., et al. 2003. Pharmacokinetics and the most suitable dosing regimen of fluconazole in critically ill patients receiving continuous hemodiafiltration. Intensive Care Med. 29:1844-1848. (Pubitemid 37373838)